Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling

Nature Communications

Volumn 8, Issue 1, 2017, Pages

  Sassi, Yassine ^a,i   Avramopoulos, Petros ^a,b   Ramanujam, Deepak ^a,b   Grüter, Laurenz ^a   Werfel, Stanislas ^a   Giosele, Simon ^a   Brunner, Andreas David ^a   Esfandyari, Dena ^a,b   Papadopoulou, Aikaterini S ^c,d   De Strooper, Bart ^c,d   Hübner, Norbert ^b,e,f   Kumarswamy, Regalla ^g   Thum, Thomas ^g   Yin, Xiaoke ^h   Mayr, Manuel ^h   Laggerbauer, Bernhard ^a   Engelhardt, Stefan ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ATRIAL NATRIURETIC FACTOR ALPHA; BIOLOGICAL MARKER; COLLAGEN; COLLAGEN TYPE 1 ALPHA 1; COLLAGEN TYPE 1 ALPHA 2; COLLAGEN TYPE 3 ALPHA 1; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN A; EARLY GROWTH RESPONSE FACTOR 1; HEPATOCYTE NUCLEAR FACTOR 3BETA; LYMPHOID ENHANCER FACTOR 1; MESSENGER RNA; MICRORNA 29; MYOSIN HEAVY CHAIN 6; MYOSIN HEAVY CHAIN 7; MYOSIN HEAVY CHAIN ALPHA; MYOSIN HEAVY CHAIN BETA; PROTEIN P53; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR ETV4; TRANSCRIPTION FACTOR NFATC3; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR TEAD2; UNCLASSIFIED DRUG; WNT PROTEIN; MICRORNA; MIRN29 MICRORNA, MOUSE;

CARDIOVASCULAR SYSTEM; CELLS AND CELL COMPONENTS; COLLAGEN; GENE EXPRESSION; HISTOPATHOLOGY; MUTATION; NUMERICAL MODEL;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTISENSE THERAPY; ARTICLE; CARDIAC MUSCLE CELL; CELL SPECIFICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION; HEART FUNCTION; HEART INJURY; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR PATHOLOGY; MOUSE; NEWBORN; NONHUMAN; RAT; TISSUE SPECIFICITY; UPREGULATION; WNT SIGNALING; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE; CARDIOMEGALY; GENETICS; KNOCKOUT MOUSE; METABOLISM; MIDDLE AGED; PATHOLOGY; SIGNAL TRANSDUCTION;

ADULT; AGED; ANIMALS; CARDIOMEGALY; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICRORNAS; MIDDLE AGED; MYOCARDIUM; MYOCYTES, CARDIAC; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 85034643982     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-017-01737-4     Document Type: Article

References (55)

1. Jonas, S. &Izaurralde, E. Towards a molecular understanding of microRNAmediated gene silencing. Nat. Rev. Genet. 16, 421-433 (2015).
2. Friedman, R. C., Farh, K. K. H., Burge, C. B. &Bartel, D. P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19, 92-105 (2009).
3. Rigoutsos, I. New tricks for animal micrornas: targeting of amino acid coding regions at conserved and nonconserved sites. Cancer Res. 69, 3245-3248 (2009).
4. Werfel, S., Leierseder, S., Ruprecht, B., Kuster, B. &Engelhardt, S. Preferential microRNA targeting revealed by in vivo competitive binding and differential Argonaute immunoprecipitation. Nucleic Acids Res. 45, 10218-10228 (2017).
5. Mendell, J. T. &Olson, E. N. MicroRNAs in stress signaling and human disease. Cell 148, 1172-1187 (2013).
6. Hata, A. Functions of microRNAs in cardiovascular biology and disease. Annu. Rev. Physiol. 75, 69-93 (2013).
7. Pellman, J., Zhang, J. &Sheikh, F. Myocyte-fibroblast communication in cardiac fibrosis and arrhythmias: Mechanisms and model systems. J. Mol. Cell Cardiol. 94, 22-31 (2016).
8. van Rooij, E. et al. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316, 575-579 (2007).
9. Carè, A. et al. MicroRNA-133 controls cardiac hypertrophy. Nat. Med. 13, 613-618 (2007).
10. Ucar, A. et al. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat. Commun. 3, 1078 (2012).
11. Duisters, R. F. et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ. Res. 104, 170-178 (2009).
12. Matkovich, S. J. et al. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressureoverloaded adult hearts. Circ. Res. 106, 166-175 (2010).
13. van Rooij, E. et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl Acad. Sci. USA 105, 13027-13032 (2008).
14. Thum, T. et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456, 980-984 (2008).
15. Ramanujam, D., Sassi, Y., Laggerbauer, B. &Engelhardt, S. Viral vector-based targeting of miR-21 in cardiac non-myocyte cells reduces pathologic remodeling of the heart. Mol. Ther. 24, 1-10 (2016).
16. Qin, W. et al. TGF-β/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J. Am. Soc. Nephrol. 22, 1462-1474 (2011).
17. Fang, Y. et al. miR-29c is downregulated in renal interstitial fibrosis in humans and rats and restored by HIF-α activation. Am. J. Physiol. Renal Physiol. 304, F1274-F1282 (2013).
18. Roderburg, C. et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 53, 209-218 (2011).
19. Wang, L. et al. Loss of miR-29 in myoblasts contributes to dystrophic muscle pathogenesis. Mol. Ther. 20, 1222-1233 (2012).
20. Maurer, B. et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum. 62, 1733-1743 (2010).
21. Cushing, L. et al. miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 45, 287-294 (2011).
22. Boon, R. A. et al. MicroRNA-29 in aortic dilation: implications for aneurysm formation. Circ. Res. 109, 1115-1119 (2011).
23. Maegdefessel, L. et al. Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development. J Clin Invest. 122, 497-506 (2012).
24. Merk, D. R. et al. miR-29b participates in early aneurysm development in Marfan syndrome. Circ. Res. 110, 312-324 (2012).
25. Zampetaki, A. et al. Role of miR-195 in aortic aneurysmal disease. Circ. Res. 115, 857-866 (2014).
26. Jentzsch, C. et al. A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes. J. Mol. Cell. Cardiol. 52, 13-20 (2012).
27. Kauffman, L. et al. Gradual rarefaction of hematopoietic precursors and atrophy in a depleted microRNA 29a, b and c environment. PLoS ONE 10, e0131981 (2015).
28. Papadopoulou, A. S. et al. The thymic epithelial microRNA network elevates the threshold for infection-associated thymic involution via miR-29a mediated suppression of the IFN-α receptor. Nat. Immunol. 13, 181-187 (2012).
29. Dooley, J. et al. The microRNA-29 family dictates the balance between homeostatic and pathological glucose handling in diabetes and obesity. Diabetes 65, 53-61 (2015).
30. Abonnenc, M. et al. Extracellular matrix secretion by cardiac fibroblasts: Role of MicroRNA-29b and MicroRNA-30c. Circ. Res. 113, 1138-1147 (2013).
31. Liao, J. Y. et al. Deep sequencing of human nuclear and cytoplasmic small RNAS reveals an unexpectedly complex subcellular distribution of mirnas and tRNA 3′ trailers. PLoS ONE 5, e10563 (2010).
32. Hwang, H.-W., Wentzel, E. A. &Mendell, J. T. A hexanucleotide element directs microRNA nuclear import. Science 315, 97-100 (2007).
33. Kamran, F. et al. Evidence that up-regulation of microRNA-29 contributes to postnatal body growth deceleration. Mol. Endocrinol. 29, 921-932 (2015).
34. Spengler, R. M. et al. Elucidation of transcriptome-wide microRNA binding sites in human cardiac tissues by Ago2 HITS-CLIP. Nucleic Acids Res. 44, 7120-7131 (2016).
35. Ganesan, J. et al. MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation 127, 2097-2106 (2013).
36. Deb, A. Cell-cell interaction in the heart via Wnt/beta-catenin pathway after cardiac injury. Cardiovasc. Res. 102, 214-223 (2014).
37. Dawson, K., Aflaki, M. &Nattel, S. Role of the Wnt-Frizzled system in cardiac pathophysiology: a rapidly developing, poorly understood area with enormous potential. J. Physiol. 591, 1409-1432 (2013).
38. Colston, J. T. et al. Wnt-induced secreted protein-1 is a prohypertrophic and profibrotic growth factor. Am. J. Physiol. Heart Circ. Physiol. 293, H1839-H1846 (2007).
39. Rao, T. P. &Kühl, M. An updated overview on wnt signaling pathways: a prelude for more. Circ. Res. 106, 1798-1806 (2010).
40. Antos, C. L. et al. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc. Natl Acad. Sci. USA 99, 907-912 (2002).
41. Matsuda, T. et al. Distinct roles of GSK-3alpha and GSK-3beta phosphorylation in the heart under pressure overload. Proc. Natl Acad. Sci. USA 105, 20900-20905 (2008).
42. Eppig, J. et al. The Mouse Genome Database (MGD): facilitating mouse as a model for human biology and disease. Nucleic Acids Res. 43, D726-D736 (2015).
43. Sampson, E. M. et al. Negative regulation of the Wnt-beta-catenin pathway by the transcriptional repressor HBP1. EMBO J. 20, 4500-4511 (2001).
44. McCrea, P. D. &Gottardi, C. J. Beyond β-catenin: prospects for a larger catenin network in the nucleus. Nat. Rev. Mol. Cell Biol. 17, 55-64 (2016).
45. Kapinas, K., Kessler, C., Ricks, T., Gronowicz, G. &Delany, A.M. miR-29 modulates Wnt signaling in human osteoblasts through a positive feedback loop. J. Biol. Chem. 285, 25221-25231 (2010).
46. Wang, J. et al. microRNA-29b prevents liver fibrosis by attenuating hepatic stellate cell activation and inducing apoptosis through targeting PI3K/AKT pathway. Oncotarget 6, 7325-7338 (2015).
47. Wang, B. et al. Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis. J. Am. Soc. Nephrol. 23, 252-265 (2012).
48. Montgomery, R. L. et al. MicroRNA mimicry blocks pulmonary fibrosis. EMBO Mol. Med. 6, 1347-1356 (2014).
49. Li, Z. &Rana, T. M. Therapeutic targeting of microRNAs: current status and future challenges. Nat. Rev. Drug Discov. 13, 622-638 (2014).
50. Gourdie, R. G., Dimmeler, S. &Kohl, P. Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease. Nat. Rev. Drug Discov. 15, 620-638 (2016).
51. Rockman, H. A. et al. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc. Natl Acad. Sci. USA 88, 8277-8281 (1991).
52. McCarrick, J. 3rd, Parnes, R., Seong, R., Solter, D. &Knowles, B. Positivenegative selection gene targeting with the diphtheria toxin A-chain gene in mouse embryonic stem cells. Transgenic Res. 2, 183-190 (1993).
53. Lee, G. &Saito, I. Role of nucleotide sequences of loxP spacer region in Cremediated recombination. Gene 216, 55-65 (1998).
54. Lakso, M. et al. Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. Proc. Natl Acad. Sci. USA 93, 5860-5865 (1996).
55. Veeman, M. T., Slusarski, D. C., Kaykas, A., Louie, S. H. &Moon, R. T. Zebrafish prickle, a modulator of noncanonical Wnt/Fz signaling, regulates gastrulation movements. Curr. Biol. 13, 680-685 (2003).